NasdaqCM:NEOHealthcare
NeoGenomics PanTracer Pro Launch Sets New Test Against Weak Share Performance
NeoGenomics, NasdaqCM:NEO, has launched PanTracer Pro, a new diagnostic solution for clinicians treating advanced stage solid tumors.
The offering combines broad genomic profiling and customized diagnostic testing into a single order with a focus on faster turnaround times.
PanTracer Pro is designed to address fragmented testing workflows, treatment delays, and incomplete biomarker assessment in cancer care.
NeoGenomics, trading at $11.38, has seen mixed share price performance, with a 30...